Klaus Hollmig

University of Arkansas for Medical Sciences

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Bart Barlogie

University of Arkansas for Medical Sciences

Guido Tricot

University of Arkansas for Medical Sciences

Frits van Rhee

University of Arkansas for Medical Sciences

Maurizio Zangari

University of Arkansas for Medical Sciences

Elias Anaissie

Clinical Trial and Consulting

John Crowley

AbbVie (United States)

Mauricio Pineda‐Roman

Levine Cancer Institute

John D. Shaughnessy

University of Arkansas for Medical Sciences

Joshua Epstein

University of Colorado Denver

Yazan Alsayed

William Harvey Research Institute

Cooperative Institutions

University of Arkansas for Medical Sciences

Cancer Research And Biostatistics

Winthrop Rockefeller Foundation

Heinrich Heine University Düsseldorf

Düsseldorf University Hospital

Fred Hutch Cancer Center

Institute for Myeloma & Bone Cancer Research

SWOG Cancer Research Network

University of Arkansas at Little Rock

University of Arkansas Medical Center

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Total Therapy 2 (TT2) for Multiple Myeloma (MM): Thalidomide (T) Effects Superior Complete Response (CR) and Event-Free Survival (EFS); Similar Overall Survival (OS) Linked to Shorter Post-Relapse Survival.

Blood (2005)

Guido Tricot Erik Rasmussen Elias Anaissie Frits van Rhee Maurizio Zangari

Melphalan

Progression-free survival

10.1182/blood.v106.11.423.423

Cite

Citations (7)

Supplementary Data from Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling

Jeffrey Haessler John D. Shaughnessy Fenghuang Zhan John Crowley Joshua Epstein

Supplementary Data from Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling

Profiling (computer programming)

Subgroup analysis

10.1158/1078-0432.22441171

Cite

Citations (0)

Total Therapies (TT) for Newly Diagnosed Patients with Multiple Myeloma (MM): Significant Benefit in High-Risk Disease with Cytogenetic Abnormalities (CA) over the Course of 17 Years.

Blood (2006)

Frits van Rhee Vanessa Bolejack Elias Anaissie Guido Tricot Klaus Hollmig

10.1182/blood.v108.11.3490.3490

Cite

Citations (1)

Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling

Clinical Cancer Research (2007)

Jeffrey Haessler John D. Shaughnessy Fenghuang Zhan John Crowley Joshua Epstein

Abstract Experimental Design: To determine whether the clinical benefit of complete remission (CR) may depend on prognostic subgroups of patients with multiple myeloma. Patients and Methods: Newly diagnosed patients with myeloma received a tandem autotransplant regimen. Using multivariate regression analyses, we examined the prognostic implications of time-dependent onset of CR on overall survival and event-free survival in the context of standard prognostic factors (SPF) and gene expression profiling–derived data available for 326 patients. Results: CR benefited patients regardless of risk status when only SPFs were examined. With knowledge of gene array data, a survival (and event-free survival) benefit of CR only pertained to the small high-risk subgroup of 13% of patients (hazard ratio, 0.23; P = 0.001), whereas the majority of patients with low-risk disease had similar survival expectations whether or not CR was achieved (hazard ratio, 0.68; P = 0.128). Conclusions: Access to gene expression information permitted the recognition of a small very high-risk subgroup of 13% of patients, in whom prolonged survival critically depended on achieving CR. Absence of such benefit in the remainder should lead to a reassessment of clinical trial designs that rely on this end point as a surrogate for long-term prognosis.

Subgroup analysis

Regimen

Surrogate endpoint

10.1158/1078-0432.ccr-07-0527

Cite

Citations (105)

MRI and Metastatic Bone Survey (MBS) Examinations in Multiple Myeloma (MM): Laboratory Correlates and Prognostic Implications for 611 Patients Receiving Total Therapy 2.

Blood (2006)

Ronald C. Walker John D. Shaughnessy Jeffery Haessler Joshua Epstein Jeffery R. Sawyer

Melphalan

10.1182/blood.v108.11.3515.3515

Cite